Salarius Pharmaceuticals Partners with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals, a subsidiary of Decoy Therapeutics, is collaborating with Texas Biomedical Research Institute to conduct in vitro testing of its peptide conjugate fusion inhibitors against influenza strains, including H5N1 avian flu. The company's IMP3ACT platform has shown strong binding affinity to the viral target, potentially positioning Salarius to address the large global commercial opportunity in anti-flu activity. The collaboration aims to expand the relationship with Texas Biomed's scientific and medical resources as the company advances its pipeline.